Table 3.

Independent-associated factors with disease activity, REM/LDA, HAQ score, and functional remission at W54.

Table 3A. Multiple linear regression analysis of SDAI, DAS28-CRP, and HAQ score at W54.
FactorsB95% CIβp
SDAI at W54, R2 = 0.3365
  Constant5.8132.502–9.12400.0006
  IFX dosage, mg/kg−0.562−0.983 – −0.142−0.1230.0089
  SDAI at W140.6060.508–0.7040.569< 0.0001
DAS28-CRP at W54, R2 = 0.4114
  Constant1.0470.578–1.5170< 0.0001
  IFX dosage, mg/kg−0.081−0.128 – −0.034−0.1500.0007
  DAS28-CRP at W140.6970.601 – 0.7930.628< 0.0001
HAQ at W54, R2 = 0.3683
  Constant−0.091−0.281–0.09900.3483
  IFX dosage, mg/kg−0.015−0.035–0.006−0.0630.1671
  HAQ at W00.3530.253–0.4520.351< 0.0001
  Disease duration, yrs0.0140.006–0.0220.1600.0008
  SDAI at W140.0190.013–0.0240.345< 0.0001
HAQ at W54, R2 = 0.3811
  Constant−0.401−0.623 – −0.18000.0004
  IFX dosage, mg/kg−0.015−0.036–0.005−0.0670.1403
  HAQ at W00.3370.238–0.4370.335< 0.0001
  Disease duration, yrs0.0140.006–0.0220.1610.0006
  DAS28-CRP at W140.1750.129–0.2210.369< 0.0001
Table 3B. Multiple logistic regression analysis of achievement of REM/LDA and functional remission at W54.
FactorsOR95% CIp
REM (SDAI) at W54, *R2 = 0.3911
  IFX dosage, mg/kg1.1271.017–1.2510.0218
  Disease duration, yrs0.9470.904–0.9870.0083
  SDAI at W140.8430.800–0.882< 0.0001
LDA (SDAI) at W54, *R2 = 0.3087
  IFX dosage, mg/kg1.1181.018–1.2320.0195
  SDAI at W140.9060.880–0.929< 0.0001
REM (DAS28-CRP) at W54, *R2 = 0.3847
  IFX dosage, mg/kg1.1561.050–1.2770.0031
  DAS28-CRP at W140.3250.241–0.424< 0.0001
LDA (DAS28-CRP) at W54, *R2 = 0.3757
  IFX dosage, mg/kg1.1231.023–1.2350.0143
  DAS28-CRP at W140.3470.264–0.445< 0.0001
Functional remission at W54, *R2 = 0.3805
  IFX dosage, mg/kg1.0650.970–1.1720.1872
  HAQ at W00.2420.147–0.386< 0.0001
  SDAI at W140.9310.905–0.955< 0.0001
Functional remission at W54, *R2 = 0.4059
  IFX dosage, mg/kg1.0780.980–1.1880.1238
  Duration of MTX use, yrs0.8800.791–0.9730.0125
  HAQ at W00.2410.145–0.387< 0.0001
  DAS28-CRP at W140.5060.395–0.637< 0.0001
  • Independent variables were selected using a backward stepwise procedure. Functional remission was defined as HAQ ≤ 0.50.

  • * Nagelkerke R2. REM: clinical remission; LDA: low disease activity; HAQ: Health Assessment Questionnaire; W54: Week 54; SDAI: Simplified Disease Activity Index; DAS28-CRP: 28-joint Disease Activity Score-C-reactive protein; B: nonstandardized coefficients; β: standardized coefficients; R2: explained variance; IFX: infliximab; W14: Week 14; W0: Week 0; MTX: methotrexate.